You are here: Industry Insights > MOR210

News List

I-Mab, MorphoSys Announce First Patient Dosed in Study of TJ210/MOR210 for Advanced Cancer americanpharmaceuticalreview
February 02, 2021
I-Mab and MorphoSys announced the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed or refractory ...
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020 prnasia
November 12, 2020
I-Mab announced new preclinical data from in vivo and in vitro studies of its C5aR antibody project, TJ210/MOR210, at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
MorphoSys, I-Mab Announce IND Application Clearance for Advanced Cancer Treatment americanpharmaceuticalreview
September 27, 2020
MorphoSys and I-Mab jointly announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...
MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer prnasia
September 18, 2020
MorphoSys AG and I-Mab jointly announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) for MorphoSys' investigational human anti-C5aR1 antibody MOR210/TJ210 for the treatment of relapsed or ...